Theratechnologies (TSE:TH) Reaches New 52-Week High - Here's What Happened

Key Points

• Theratechnologies Inc. shares reached a new 52-week high of C$4.34, indicating recent positive performance in the stock market.
• Analysts at Jones Trading downgraded Theratechnologies from a "strong-buy" rating to a "hold" rating, suggesting a more cautious outlook for investors.
• The company, which focuses on specialized pharmaceuticals for HIV patients, has two approved products: EGRIFTA and Trogarzo.
• Theratechnologies holds a market capitalization of C$138.47 million, with significant financial ratios including a P/E ratio of -49.13.

Shares of Theratechnologies Inc. (TSE:TH - Get Free Report) reached a new 52-week high during trading on Friday . The company traded as high as C$4.34 and last traded at C$4.34, with a volume of 36723 shares. The stock had previously closed at C$4.29.

Analysts Set New Price Targets

Separately, Jones Trading lowered Theratechnologies from a "strong-buy" rating to a "hold" rating in a research note on Thursday, July 3rd.

Theratechnologies Trading Up 0.2%

The firm has a market cap of C$138.79 million, a PE ratio of -49.24, a price-to-earnings-growth ratio of -8.50 and a beta of 1.73. The company has a current ratio of 1.08, a quick ratio of 0.64 and a debt-to-equity ratio of -293.92. The company has a 50-day simple moving average of C$3.78 and a 200 day simple moving average of C$3.10.

Theratechnologies Company Profile

Theratechnologies Inc is a specialty pharmaceutical company that addresses the unmet medical needs of HIV patients. It mainly operates in Canada and the United States. The company has two approved products, EGRIFTA marketed in Canada and the United States, and Trogarzo approved for commercialization in the United States.